Our top pick for
DaVita Inc is a medical care facilities business based in the US. DaVita shares (DVA) are listed on the NYSE and all prices are listed in US Dollars. DaVita employs 67,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$110.92|
|52-week range||$84.14 - $134.47|
|50-day moving average||$118.71|
|200-day moving average||$121.10|
|Wall St. target price||$140.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$7.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-17)||N/A|
|1 month (2021-09-28)||-8.66%|
|3 months (2021-07-28)||-6.66%|
|6 months (2021-04-28)||-2.11%|
|1 year (2020-10-28)||28.57%|
|2 years (2019-10-28)||91.77%|
|3 years (2018-10-26)||70.44%|
|5 years (2016-10-28)||101.09%|
Valuing DaVita stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DaVita's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DaVita's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, DaVita shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
DaVita's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7768. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DaVita's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DaVita's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.4 billion.
The EBITDA is a measure of a DaVita's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$11.6 billion|
|Operating margin TTM||14.98%|
|Gross profit TTM||$3.6 billion|
|Return on assets TTM||5.84%|
|Return on equity TTM||34.47%|
|Market capitalisation||$12.1 billion|
TTM: trailing 12 months
There are currently 2.7 million DaVita shares held short by investors – that's known as DaVita's "short interest". This figure is 6.7% up from 2.6 million last month.
There are a few different ways that this level of interest in shorting DaVita shares can be evaluated.
DaVita's "short interest ratio" (SIR) is the quantity of DaVita shares currently shorted divided by the average quantity of DaVita shares traded daily (recently around 682744.13965087). DaVita's SIR currently stands at 4.01. In other words for every 100,000 DaVita shares traded daily on the market, roughly 4010 shares are currently held short.
However DaVita's short interest can also be evaluated against the total number of DaVita shares, or, against the total number of tradable DaVita shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DaVita's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 DaVita shares in existence, roughly 30 shares are currently held short) or 0.0401% of the tradable shares (for every 100,000 tradable DaVita shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DaVita.
Find out more about how you can short DaVita stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DaVita.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 20.07
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DaVita's overall score of 20.07 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DaVita is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.6/100
DaVita's environmental score of 2.6 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that DaVita is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 10.68/100
DaVita's social score of 10.68 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that DaVita is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 7.8/100
DaVita's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that DaVita is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DaVita scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DaVita has, for the most part, managed to keep its nose clean.
|Total ESG score||20.07|
|Total ESG percentile||24.1|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
We're not expecting DaVita to pay a dividend over the next 12 months.
DaVita's shares were split on a 2:1 basis on 8 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DaVita shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DaVita shares which in turn could have impacted DaVita's share price.
Over the last 12 months, DaVita's shares have ranged in value from as little as $84.14 up to $134.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DaVita's is 1.3106. This would suggest that DaVita's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.